Spots Global Cancer Trial Database for A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
Official Title: A Phase II, Randomized, Open-label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First-line Therapy for Unresectable Pleural Mesothelioma in Chinese Participants
Study ID: NCT05136677
Conditions
Study Description
Brief Summary: The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 0009, Beijing, Beijing, China
Local Institution - 0013, Harbin, Heilongjiang, China
The First Affiliated Hospital of Zhengzhou Universtiy-Oncology department, Zhengzhou, Henan, China
Local Institution - 0008, Changsha, Hunan, China
Local Institution - 0005, Changsha, Hunan, China
Local Institution - 0023, Wuhan, Hunan, China
Local Institution - 0036, Hohhot, Inner Mongolia, China
Northern Jiangsu People's Hospital-General Surgery Department, Yangzhou, Jiangsu, China
The First Hospital of Jilin University, Changchun, Jilin, China
Local Institution - 0019, Shenyang, Liaoning, China
Liaoning Cancer Hospital-Oncology, Shenyang, Liaoning, China
Local Institution - 0021, Shenyang, Liaoning, China
Local Institution - 0037, Jinan, Shandong, China
Local Institution - 0030, Qingdao, Shandong, China
Shanghai Chest Hospital, Shanghai, Shanghai, China
Local Institution - 0034, Shanghai, Shanghai, China
Local Institution - 0033, Taiyuan, Shanxi, China
Sichuan Cancer hospital, Chengdu, Sichuan, China
Tianjin Medical University General Hospital-Oncology Department, Tianjin, Tianjin, China
Tianjin Medical University Cancer Institute and Hospital-lung cancer, Tianjin, Tianjin, China
Yunnan Province Cancer Hospital, Kunming, Yunnan, China
The First Affiliated Hospital, Zhejiang University-Respiratory Department, Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital-Thoracic Surgery, Hangzhou, Zhejiang, China
Local Institution - 0012, Ningbo, Zhejiang, China
Ningbo Medical Center-respiratory, Ningbo, Zhejiang, China
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
